ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Clinical trials for ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Tough-to-Treat leukemia: multiple drug cocktails tested
Disease control Recruiting nowThis phase II trial tests several experimental drug combinations against the standard treatment for high-risk acute myeloid leukemia (AML) in patients aged 59 or younger. The goal is to see if newer regimens, including venetoclax and liposome formulations, can better shrink cance…
Matched conditions: ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug combo aims to keep childhood leukemia at bay after transplant
Disease control Recruiting nowThis phase 1 trial tests the safety and best dose of an oral drug called ASTX727 (a combination of cedazuridine and decitabine) along with filgrastim in children with high-risk acute myeloid leukemia (AML) that has returned or not responded to treatment. All participants have alr…
Matched conditions: ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for tough blood cancers: first human trial launches
Disease control Recruiting nowThis study tests a new drug called STX-0712 in people with advanced types of blood cancer (CMML or AML) who have run out of standard treatments. The main goal is to find a safe dose and see how the body handles the drug. About 105 participants will take part in this early-phase t…
Matched conditions: ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Phase: PHASE1 • Sponsor: Solu Therapeutics, Inc • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New screening trial aims to speed up matching of cancer patients to the right treatments
Knowledge-focused Recruiting nowThis study tests a new way to screen patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) by analyzing their bone marrow and blood for specific biomarkers. The goal is to quickly match patients with a treatment trial that targets their cancer's unique mark…
Matched conditions: ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
New screening trial aims to match kids with relapsed leukemia to targeted therapies
Knowledge-focused Recruiting nowThis study screens children and young adults up to age 22 whose leukemia has returned or is hard to treat. By testing their blood and bone marrow, doctors can identify specific genetic markers to match them with the most promising experimental treatments. The goal is to build a r…
Matched conditions: ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Phase: PHASE1, PHASE2 • Sponsor: PedAL BCU, LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC